Fallopian Tube Neoplasms: all 734 studies
Page 2 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruitingNCT05071937Phase 2
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruitingNCT05059444
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingNCT05009082Phase 3
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian CancerRecruitingNCT04811703Phase 1
- Developing a Test of Uterine Lavage for the Detection of Ovarian CancerRecruitingNCT04794322
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingNCT04701645Phase 1
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsRecruitingNCT04657068Phase 1/2
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingNCT04590326Phase 1/2
- Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialRecruitingNCT04575935Phase 3
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingNCT04516447Phase 1
- Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)Not yet recruitingNCT04515602Phase 3
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingNCT04469764Phase 2
- Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer PatientsRecruitingNCT04375956Phase 2
- BP1001-A in Patients With Advanced or Recurrent Solid TumorsRecruitingNCT04196257Phase 1
- MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)RecruitingNCT04111978Phase 3
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingNCT04055649Phase 2
- Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting HypoxiaRecruitingNCT04001023Not applicable
- Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)RecruitingNCT03983226Phase 2
- Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal CancersRecruitingNCT03976999Not applicable
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
- Determining Prognostic Immune Markers in Patients With Ovarian CancerRecruitingNCT03862677
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFRecruitingNCT03604315Phase 1
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingNCT03564340Phase 1/2
- HIPEC After Initial CRS in Patients Who Have Received NACTRecruitingNCT03540017Phase 1
- Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2RecruitingNCT03296826
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruitingNCT00005095
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
- A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT05613088Phase 2Results posted
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersCompletedNCT05483933Phase 1Results posted
- Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingNCT05276973Phase 1Results posted
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05261490Phase 1/2Results posted
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingNCT05257408Phase 3Results posted
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).Active, not recruitingNCT05116189Phase 3Results posted
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3Results posted
- Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedNCT05041257Phase 2Results posted
- Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results posted
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
- CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3Results posted
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedNCT04611126Phase 1/2Results posted
- BrUOG 390: Neoadjuvant Treatment With TalazoparibTerminatedNCT04598321Phase 1Results posted
- Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyCompletedNCT04539327Results posted
- A Study of NM21-1480 in Adult Patients With Advanced Solid TumorsTerminatedNCT04442126Phase 1/2Results posted
- Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal ChemotherapyCompletedNCT04415944Phase 2Results posted
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerCompletedNCT04406623Phase 1Results posted
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedNCT04296890Phase 3Results posted
- Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor SitesStatus unknownNCT04267575Not applicableResults posted
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionCompletedNCT04209855Phase 3Results posted
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT04034927Phase 2Results posted
- AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
- A Trial Evaluating TG4050 in Ovarian Carcinoma.CompletedNCT03839524Phase 1Results posted
- A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
- European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerCompletedNCT03783949Phase 2Results posted
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03776812Phase 2Results posted
- Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerCompletedNCT03759600Phase 2Results posted
- Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerCompletedNCT03759587Phase 2Results posted
- Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)CompletedNCT03740165Phase 3Results posted
- A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)CompletedNCT03657043Phase 2Results posted
- A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03635489Phase 3Results posted
- Study of ADCT-301 in Patients With Selected Advanced Solid TumorsTerminatedNCT03621982Phase 1Results posted
- Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of MalignancyCompletedNCT03593681Results posted
- MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03585764Phase 1Results posted
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3Results posted
- A Study of PF-06873600 in People With CancerTerminatedNCT03519178Phase 1/2Results posted
- Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian CancerCompletedNCT03480750Phase 1/2Results posted
- Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT03430700Phase 2Results posted
- Anti-PD-L1 and SAbR for Ovarian CancerTerminatedNCT03312114Phase 2Results posted
- A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03206047Phase 1/2Results posted
- Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03188432Phase 2Results posted
- Evaluation of Weekly Ixabepilone With or Without Biweekly BevacizumabCompletedNCT03093155Phase 2Results posted
- IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
- CAR T Cells in Mesothelin Expressing CancersCompletedNCT03054298Phase 1Results posted
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03038100Phase 3Results posted
- IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing SurgeryTerminatedNCT03029611Phase 2Results posted
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results posted
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerTerminatedNCT02948426Phase 1Results posted
- Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerCompletedNCT02915523Phase 1/2Results posted
- Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.CompletedNCT02903771Phase 1Results posted
- A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
- Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3Results posted
- Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02839707Phase 2/3Results posted
- Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).TerminatedNCT02834975Phase 2Results posted
- Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedNCT02759588Phase 1/2Results posted
- A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersCompletedNCT02728830Early Phase 1Results posted
- Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
- A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological CancerTerminatedNCT02661815Phase 1Results posted
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
- Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Active, not recruitingNCT02650986Phase 1/2Results posted
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
- Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02627443Phase 1Results posted
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
- Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02595892Phase 2Results posted
- Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02520154Phase 2Results posted
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted